- Home
- SLP
as 05-09-2025 4:00pm EST
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 708.1M | IPO Year: | 1997 |
| Target Price: | $47.83 | AVG Volume (30 days): | 448.0K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | 0.36 | EPS Growth: | -30.71 |
| 52 Week Low/High: | $23.01 - $51.22 | Next Earning Date: | 07-01-2025 |
| Revenue: | $78,564,000 | Revenue Growth: | 21.49% |
| Revenue Growth (this year): | 30.38% | Revenue Growth (next year): | 11.97% |
Stock Insider Trading Activity of Simulations Plus Inc. (SLP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WOLTOSZ WALTER S | SLP | Director10% Owner | May 1 '25 | Sell | $33.49 | 20,000 | $670,150.32 | 3,354,761 | |
| WOLTOSZ WALTER S | SLP | Director10% Owner | Apr 1 '25 | Sell | $24.32 | 20,000 | $481,786.00 | 3,354,761 | |
| WOLTOSZ WALTER S | SLP | Director10% Owner | Mar 3 '25 | Sell | $28.68 | 20,000 | $573,600.00 | 3,354,761 |
Latest Simulations Plus Inc. News
SLP Breaking Stock News: Dive into SLP Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
SLP: Lowering target price to $30.00
TipRanks
17 days ago
2 ‘Strong Buy’ Stocks That Are Crashing the Market in April
Argus Research
17 days ago
SLP: Raising target price to $37.00
Business Wire
19 days ago
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
Argus Research
24 days ago
SLP: Raising target price to $34.00
Argus Research
a month ago
SLP: What does Argus have to say about SLP?
Simply Wall St.
a month ago
3 Leading Stocks Estimated To Be Up To 45.9% Below Intrinsic Value
Thomson Reuters StreetEvents
a month ago
Q2 2025 Simulations Plus Inc Earnings Call
Compare SLP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLP Simulations Plus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.